English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Recently, a study reported significant reductions in metachronous gastric cancer after H. pylori eradication therapy in patients with previously resected early gastric cancer. These results indicated thatH. pylori infections benefit from treatment at any stage, thus refuting the conventional concept of the “point of no return”. Unfortunately, several methodological problems may exist in the aforementioned study that may influence the generalizability of results and conclusions and impede its broader clinical use. In this study, we discuss in detail methodological problems and rationale for caution by analyzing reported studies, aiming to help the promotion of future well-powered trials. Helicobacter pylori infection is a major health concern worldwide, especially in many resourcepoor countries, particularly in Africa and Latin America/Caribbean, such that more than half of the global population was infected with the pathogen H. pylori in 2015 (1). Gastric cancer (for which stomach adenocarcinoma accounts for around 90% of cases) is a life-threatening disease, whichmay be prevented by pharmacological approaches such as aspirin and non-pharmacological approaches such as gastric endoscopy (1). Basic and clinical studies have demonstrated strong associations between oncogenesis and the presence of H. pylori bacteria in the stomach; this includes the progression of pre-cancerous lesions (2). Remarkably, the proportion of non-cardia gastric cancer attributable to H. pylori increased from 74.7 to 89.0% from 2008 to 2014 (3). Furthermore, other epidemiologic factors, such as metabolic syndrome, are increasingly implicated in the etiology of gastric cancer (4). Importantly, H. pylori infection has also been linked to non-gastric diseases, including Parkinson’s disease (5). The eradication ofH. pylori using antibiotic therapymay prevent gastric cancer; such treatment has been implemented with varying levels of success globally (6).

Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage